Adequate data were available for pooled analyses of two additional types of systemic treatment, namely treatment with EGFR-TKIs in lung cancer and treatment with immunotherapy using PD-1 or PD-L1 inhibitors. This evidence concerns the gene EGFR and lung carcinoma.